While the choice of treatment for diabetic retinopathy/diabetic macular edema (DR/DME) is largely based on the experience and preference of the treating retinal specialist and patient preferences, payers are key stakeholders in impacting treatment selection through formulary placement, step therapy, and site-of-care policies which can affect member access. Based on findings from the 2022-2023 ManagedCareEye.com initiatives, disease state baseline knowledge and awareness has improved, but payers continue to need additional education to apply health plan best practices to improve DR/DME management and outcomes.
- Provider:Medical Education Resources
- Activity Link: https://www.managedcareeye.com/
- Start Date: 2024-06-30 05:00:00
- End Date: 2024-06-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 9997.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest